Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
A 2026 Cochrane review examined thymosin-α1 for chronic hepatitis B. Learn what researchers found about its potential benefits and current evidence limitations.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may directly protect neurons via orexin receptor signaling. Learn what this study means for stroke and neuroprotection.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may protect neurons by engaging orexin receptors and suppressing necroptosis. Learn what the study found and its implications.
By Peptide Association Research Team
New research explores how IL-15 and Thymosin α1 may reduce immune cell aging in hepatocellular carcinoma. Learn what the findings mean for patients.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may restore cancer-fighting immunity suppressed by chemotherapy. Learn what this 2026 study found and why it matters.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may help restore anti-tumor immunity after chemotherapy by activating dendritic cells. Learn what the study found.
By Peptide Association Research Team
A deep dive into thymosin alpha-1, the endogenous thymic peptide with decades of clinical research supporting its role in immune modulation, viral infections, and as an immunotherapy adjunct.
By Peptide Association Editorial Team